Scholars Central

EditorialPublished 2016

Biosimilars: The Road Ahead

Authors: Phani Kishore Thimmaraju

Insights in Biomedicine

Volume 1 · Issue 1

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Biosimilars came into existence with the sole ideology of affordable medication for chronic illnesses in the therapy areas of immunology and oncology. The increasingly austere measures and continuous cuts in healthcare budget by many countries forced pharmaceutical companies to develop low cost biologics without compromising on quality. Numerous players have entered this field sensing the wide range of opportunities in multiple therapy areas. The first generation biosimilars emerged, applying the phenomenon of incremental innovation, categorized under hormones (somatropin). Later, the copies of complex mAbs (monoclonal antibodies) were developed. Presently, multiple biosimilars exist for somatropin and epoetin. Recently, the biosimilar of infliximab (Remicade) was approved by the EMA. The Remicade biosimilar, known as Inflectra/Remsima, was jointly developed by Celltroin and Hospira.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Insights in Biomedicine.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalInsights in Biomedicine
  • BylineArticles whose byline prints “Phani Kishore Thimmaraju”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels